Test Price
2,800 AED✅ Home Collection Available
FGB Gene Congenital Afibrinogenemia Genetic Test in UAE | 2,800 AED | DHA Licensed
Executive Summary & Core Metrics
Core Diagnostics Summary
- Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO accredited next-generation sequencing.
- Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Post-test telephonic result interpretation and genetic counselling by a board-certified medical geneticist.
- Direct Billing: Insurance verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This advanced molecular diagnostic test sequences the entire FGB gene to detect pathogenic variants responsible for congenital afibrinogenemia, a rare autosomal recessive bleeding disorder characterised by complete absence of fibrinogen. Next-generation sequencing (NGS) provides a definitive molecular diagnosis, enabling precise genotype-phenotype correlation, lifelong management planning, and carrier screening for at-risk family members.
| Feature | Our NGS Test | Closest Alternative (Coagulation Panel) |
|---|---|---|
| Precision / Specificity | 99.9% sensitivity – full gene sequencing | ~75% – functional assays only |
| Method | Next‑Generation Sequencing (NGS) | Fibrinogen antigen and activity assays |
| Turnaround Time | 3–4 weeks (definitive result) | 5–7 days (variable, often inconclusive) |
| Clinical Insight | Genotype–phenotype correlation, family screening | Requires additional genetic confirmation |
Sample Requirements and Pre-Test Preparation
Accepted specimens include whole blood collected in EDTA tubes, extracted genomic DNA, or a single blood spot on an FTA card. A detailed personal and family bleeding history is required prior to testing. A mandatory pre-test genetic counselling session with a board-certified genetic counsellor will be conducted to construct a three-generation pedigree and ensure informed consent. No fasting is necessary; patients should continue routine medications unless advised otherwise by their physician.
Physician Insight & Safety Protocols
“A definitive molecular diagnosis of congenital afibrinogenemia through FGB gene sequencing provides the foundation for lifelong haemostatic management and informed family planning. However, this genetic result must always be interpreted alongside the patient’s clinical bleeding phenotype and routine coagulation parameters. The test does not replace emergency care—any episode of uncontrolled bleeding warrants immediate medical attention. Patients must never discontinue prescribed therapies without consulting their haematologist or genetic specialist.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Therapeutic Advisory – Medication Continuity
⚠ Medication Advisory
Do not pause, alter, or stop any prescribed anticoagulant, antifibrinolytic, or haemostatic therapy without explicit direction from your treating physician. Sudden discontinuation may provoke severe thrombotic or haemorrhagic complications.
Exclusion Criteria and Emergency Red Flags
- This test is not a substitute for acute bleeding management; if you are actively bleeding, proceed immediately to the nearest emergency department.
- Not indicated for minors without prior genetic counselling and guardian consent in accordance with Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Patients with severe needle phobia or inability to safely provide a blood or DNA sample may require alternative collection arrangements.
- Red Flags – Seek Urgent Care: sudden severe bruising, prolonged bleeding from minor wounds, visible blood in urine or stool, or signs of haemorrhagic shock (cold clammy skin, rapid pulse, confusion, syncope).
Patient FAQ & Clinical Guidance
1. What is the FGB gene congenital afibrinogenemia NGS test?
This DNA analysis detects disease-causing mutations in the FGB gene to confirm hereditary afibrinogenemia, a condition where fibrinogen—a critical clotting protein—is completely absent from the bloodstream. Establishing a genetic diagnosis guides long-term prophylactic therapy and enables targeted screening of at-risk relatives.
2. How does next-generation sequencing improve diagnosis over routine coagulation assays?
NGS reads the complete FGB gene sequence in a single assay, identifying rare, novel, or compound heterozygous variants that functional fibrinogen assays cannot detect. This provides a definitive molecular diagnosis and eliminates diagnostic uncertainty from borderline or inconclusive coagulation results.
3. What specimens are accepted and how can I schedule a home collection?
We accept whole blood in EDTA tubes, extracted DNA, or a single blood drop on an FTA card. To arrange a temperature-controlled cold-chain home collection with VIP mobile phlebotomy, message +971 54 548 8731 on WhatsApp. Our team operates daily from 8 AM to 11 PM and will coordinate a convenient time slot.
4. Will my insurance cover this genetic test?
Coverage varies by insurer and policy. Our billing team can verify your direct billing eligibility via WhatsApp at +971 54 548 8731. Please have your insurance card and policy number ready for a rapid pre-authorisation check before sample collection.
UAE Regulatory & Data Privacy Adherence
Legal and Compliance Framework
DNA Labs UAE operates under DHA Facility License Number 1143 and adheres to all federal healthcare data protection statutes. All genetic data is processed in accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety, patient consent, and medical liability practices are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genetic information is encrypted, access-controlled, and never shared with third parties without your explicit written consent.
Clinical & Logistical Metadata
| Test Name | FGB Gene Congenital Afibrinogenemia Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or FTA Card Blood Spot |
| Methodology Used | Next-Generation Sequencing (NGS) |
| ICD-10-CM Code | D68.2 |
| LOINC Code | 21636-6 |
| DHA Facility License & Laboratory Address | License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians